We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Respiratory syncytial virus vaccination in older adults.
- Authors
Killikelly, April; Siu, Winnie; Abrams, Elissa M.; Salvadori, Marina I.
- Abstract
This article discusses the importance of respiratory syncytial virus (RSV) vaccination in older adults. Older adults are at a higher risk of severe illness and hospitalization due to RSV, especially those over 75 years old or with comorbid conditions. Vaccination has been shown to prevent RSV-related lower respiratory tract illness in older adults, with efficacy rates ranging from 66.7% to 82.6%. While there is a small potential risk of neuroinflammatory events associated with vaccination, the benefits outweigh the risks for frail older adults or those with chronic medical conditions. The National Advisory Committee on Immunization recommends RSV vaccination for adults aged 75 years and older, as well as adults aged 60 years and older in nursing homes and chronic care facilities. One dose of the vaccine provides protection for at least 2 years, and the timing of a second dose is currently not recommended.
- Subjects
OLDER people; RESPIRATORY syncytial virus infection vaccines; RESPIRATORY syncytial virus infections; NURSING home patients; RESPIRATORY syncytial virus
- Publication
Canadian Medical Association Journal (CMAJ), 2024, Vol 196, Issue 29, pE1011
- ISSN
0820-3946
- Publication type
Article
- DOI
10.1503/cmaj.240906